



Mark Higham, *Four Seasons*
As an artist with schizophrenia, Mark hopes his artwork
will challenge public perception of mental illness.



Confidentiality Statement

The information in this document contains trade secrets and commercial information that are privileged or confidential, and may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the information is disclosed must be informed that the information is *proprietary* or *confidential* and may not be further disclosed by them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as *proprietary* or *confidential*.


Safety

Central number: 2444

Emergency signal evacuate the building (central locations/building):




End of signal:



Stay with your host

Johnson & Johnson




<https://www.youtube.com/watch?v=cjbPpoM4Hlk>

Dr. Paul Janssen (1926 – 2003)

- Stichter van Janssen Pharmaceutica N.V.
- Een van de meest vooraanstaande onderzoekers naar nieuwe therapeutica
 - 22 Eredocoraten
 - Houder van meer dan 100 patenten
 - Meer dan 850 wetenschappelijke publicaties
- Dr Paul Janssen startte eigen onderzoekswerk in 1953
- Janssen Pharmaceutica is deel van de Johnson & Johnson groep sinds 1961

<https://www.youtube.com/watch?v=leFAj0LzDU8>



How We Operate

3 VALUE STREAMS

E-t-E Accountability for product development & clinical supply

 **LARGE MOLECULES**

 **SMALL MOLECULES**

 **CLINICAL SUPPLY CHAIN**

4 MATRIX FUNCTIONS


CHINA PDMS

**STRATEGIC
BUSINESS
SUPPORT**

**EXTERNAL
INNOVATION &
STRATEGIC
SCIENCE**

**PRIMARY
CONTAINER &
DEVICE**

Clinical Supply Chain Organization



2015 outlook



60.000 patients

1.100.000 packs

360 trials
ongoing

3.150
batches


47.000
shipments

15-25%
growth


130 trials
starting

350 MM USD annual budget

Our J&J CSC Network



Beerse IMP productie en analyse locaties



● YOU ARE HERE